目的：探索弥漫性大B细胞淋巴瘤患者周围血液样本中可溶性Siglec-5 / CD163与临床特征及预后之间的临床关联。方法：通过细胞因子阵列表征外周血中显著升高的细胞因子，并通过ELISA进行验证。结果：与CD163相比，Siglec-5在根据总生存期和无进展生存期将患者区分为低风险和高风险亚组方面表现出优越性。此外，Siglec-5是利妥昔单抗加环磷酰胺，多柔比星，长春新碱和泼尼松（R-CHOP）治疗疗效的指标。结论：Siglec-5可能被应用为可靠的独立免疫指标，用于总生存期和无进展生存期。它还可以预测弥漫性大B细胞淋巴瘤中R-CHOP的疗效。

Aims: To explore the clinical association between soluble Siglec-5/CD163 and clinical feature and prognosis in peripheral blood samples of patients with diffuse large B-cell lymphoma. Method: Significantly elevated cytokines in peripheral blood were characterized by cytokines array and validated by ELISA. Results: Compared with CD163, Siglec-5 exhibited superiority in discriminating patients into low- and high-risk subgroups based on overall survival and progression-free survival. In addition, Siglec-5 was an indicator of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) treatment efficacy. Conclusion: Siglec-5 may be applied as a reliable independent immune indicator for overall survival and progression-free survival. It may also predict R-CHOP efficacy in diffuse large B-cell lymphoma.